[
    {
        "id": "79952249-7344-37ac-8663-1567a0025faf",
        "content": {
            "id": "79952249-7344-37ac-8663-1567a0025faf",
            "contentType": "STORY",
            "title": "uniQure Full Year 2024 Earnings: Misses Expectations",
            "description": "",
            "summary": "uniQure ( NASDAQ:QURE ) Full Year 2024 Results Key Financial Results Revenue: US$27.1m (up 71% from FY 2023). Net loss...",
            "pubDate": "2025-03-01T12:18:51Z",
            "displayTime": "2025-03-01T12:18:51Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
                "originalWidth": 945,
                "originalHeight": 636,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
                        "width": 945,
                        "height": 636,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/5K6kmrQzRk.k.11fs9N_QA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Simply Wall St.",
                "url": "https://simplywall.st/"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-full-2024-earnings-misses-121851835.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-full-2024-earnings-misses-121851835.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "15db96eb-a79d-34bd-9864-fb32ba856741",
        "content": {
            "id": "15db96eb-a79d-34bd-9864-fb32ba856741",
            "contentType": "STORY",
            "title": "UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates",
            "description": "",
            "summary": "uniQure (QURE) delivered earnings and revenue surprises of -240.91% and 85.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
            "pubDate": "2025-02-27T13:35:04Z",
            "displayTime": "2025-02-27T13:35:04Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248",
                "originalWidth": 900,
                "originalHeight": 467,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248",
                        "width": 900,
                        "height": 467,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/rkeQDWhJO5YQoC8FZM3hkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Zacks",
                "url": "http://www.zacks.com/"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-qure-reports-q4-loss-133504421.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-qure-reports-q4-loss-133504421.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "0fd33901-9f3d-3f90-8418-31a5cc4e7ab4",
        "content": {
            "id": "0fd33901-9f3d-3f90-8418-31a5cc4e7ab4",
            "contentType": "STORY",
            "title": "uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%",
            "description": "",
            "summary": "Key Insights Given the large stake in the stock by institutions, uniQure's stock price might be vulnerable to their...",
            "pubDate": "2025-02-20T10:44:31Z",
            "displayTime": "2025-02-20T10:44:31Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
                "originalWidth": 1194,
                "originalHeight": 432,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
                        "width": 1194,
                        "height": 432,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/cLHUTNMUETrscnKKkJfS_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Simply Wall St.",
                "url": "https://simplywall.st/"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-n-v-nasdaq-qure-104431498.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-n-v-nasdaq-qure-104431498.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "71be57d5-ebf4-32a9-a13c-185119ceb705",
        "content": {
            "id": "71be57d5-ebf4-32a9-a13c-185119ceb705",
            "contentType": "STORY",
            "title": "uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years",
            "description": "",
            "summary": "CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients. The data showed that through four years, Hemgenix continues to deliver elevated and sustained factor IX activity levels, can offer long-term and greater bleed protection compared to prophylactic treatment, can eliminate the need for ro",
            "pubDate": "2025-02-07T18:04:43Z",
            "displayTime": "2025-02-07T18:04:43Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/Benzinga/81e6861a63cb91aa16ab5654fc9ad6a8",
                "originalWidth": 983,
                "originalHeight": 553,
                "caption": "uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/Tu4bB2eI5XzoHDbzzsS8Ag--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/81e6861a63cb91aa16ab5654fc9ad6a8",
                        "width": 983,
                        "height": 553,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/GRypmpsZVzqgcoKyDzJK6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/81e6861a63cb91aa16ab5654fc9ad6a8",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Benzinga",
                "url": "http://www.benzinga.com/"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-csl-behrings-hemophilia-gene-180443838.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-csl-behrings-hemophilia-gene-180443838.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "261e0c56-5f02-3637-84dc-38c977b1f53f",
        "content": {
            "id": "261e0c56-5f02-3637-84dc-38c977b1f53f",
            "contentType": "STORY",
            "title": "Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?",
            "description": "",
            "summary": "We recently published a list of 12 Most Promising Growth Stocks According to Wall Street Analysts. In this article, we are going to take a look at where uniQure N.V. (NASDAQ:QURE) stands against other most promising growth stocks according to Wall Street analysts. Strategist Believes the Street is Underestimating the Tech Sector The new regulatory [\u2026]",
            "pubDate": "2025-01-27T22:14:21Z",
            "displayTime": "2025-01-27T22:14:21Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                "originalWidth": 1456,
                "originalHeight": 816,
                "caption": "Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/DhFc_TomAMkb6KtKuRNw.A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                        "width": 1456,
                        "height": 816,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/08eZkM.uU7IpFFFx.J7YIQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Insider Monkey",
                "url": "http://www.insidermonkey.com"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-n-v-qure-most-221421015.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-n-v-qure-most-221421015.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "d33fece8-fdf0-3e83-9996-9c3227e969f1",
        "content": {
            "id": "d33fece8-fdf0-3e83-9996-9c3227e969f1",
            "contentType": "STORY",
            "title": "Here\u2019s Why uniQure N.V. (QURE) Is Skyrocketing",
            "description": "",
            "summary": "We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where uniQure N.V. (NASDAQ:QURE) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent [\u2026]",
            "pubDate": "2025-01-13T21:17:23Z",
            "displayTime": "2025-01-13T21:17:23Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                "originalWidth": 1456,
                "originalHeight": 816,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/DhFc_TomAMkb6KtKuRNw.A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                        "width": 1456,
                        "height": 816,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/08eZkM.uU7IpFFFx.J7YIQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Insider Monkey",
                "url": "http://www.insidermonkey.com"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/why-uniqure-n-v-qure-211723136.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/why-uniqure-n-v-qure-211723136.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "2f8ee1f9-faa2-3409-ae1e-bce45bb459f7",
        "content": {
            "id": "2f8ee1f9-faa2-3409-ae1e-bce45bb459f7",
            "contentType": "STORY",
            "title": "Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?",
            "description": "",
            "summary": "We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold in 2025. In this article, we are going to take a look at where uniQure N.V. (NASDAQ:QURE) stands against the other growth stocks. The Future of Rate Cuts in 2025 The latest data from the job market in the United States [\u2026]",
            "pubDate": "2025-01-12T01:01:24Z",
            "displayTime": "2025-01-12T01:01:24Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                "originalWidth": 1456,
                "originalHeight": 816,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/DhFc_TomAMkb6KtKuRNw.A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                        "width": 1456,
                        "height": 816,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/08eZkM.uU7IpFFFx.J7YIQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2592490944de9de2cec2895cc7524f09",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Insider Monkey",
                "url": "http://www.insidermonkey.com"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-n-v-qure-among-010124511.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-n-v-qure-among-010124511.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "6904078c-6e64-38c1-86e3-cdaabf188d42",
        "content": {
            "id": "6904078c-6e64-38c1-86e3-cdaabf188d42",
            "contentType": "STORY",
            "title": "uniQure price target raised to $32 from $12 at Stifel",
            "description": "",
            "summary": "Stifel analyst Paul Matteis raised the firm\u2019s price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is \u201ccompelled\u201d by the already developing efficacy signal/trends at 24-months where uniQure got alignment with the FDA and continuing RMAT plus CBER tailwinds, which it thinks make the set up \u201cbullish\u201d as uniQure moves towards filing a BLA, the analyst tells investors. Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking finan",
            "pubDate": "2024-12-17T12:20:41Z",
            "displayTime": "2024-12-17T12:20:41Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
                "originalWidth": 192,
                "originalHeight": 192,
                "caption": "https://www.tipranks.com/news/the-fly/uniqure-price-target-raised-to-32-from-12-at-stifel",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
                        "width": 192,
                        "height": 192,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/Y7rdl760SmrhRB_Na2NO3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "TipRanks",
                "url": "https://www.tipranks.com/"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-price-target-raised-32-122041557.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/uniqure-price-target-raised-32-122041557.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "e7e146b2-fa79-3bf4-9d4a-9b2b3af88365",
        "content": {
            "id": "e7e146b2-fa79-3bf4-9d4a-9b2b3af88365",
            "contentType": "STORY",
            "title": "Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?",
            "description": "",
            "summary": "Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring.  Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.  During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025.",
            "pubDate": "2024-12-15T09:31:00Z",
            "displayTime": "2024-12-15T09:31:00Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ac5dd253d7345f9be3fef724354ae695",
                "originalWidth": 2120,
                "originalHeight": 1414,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/7nEu6wLQ2i2Edo.HbT6FuQ--~B/aD0xNDE0O3c9MjEyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/ac5dd253d7345f9be3fef724354ae695",
                        "width": 2120,
                        "height": 1414,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/AySRW6dUQy6Jsl1In2Jq3g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ac5dd253d7345f9be3fef724354ae695",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Motley Fool",
                "url": "http://www.fool.com/"
            },
            "canonicalUrl": {
                "url": "https://www.fool.com/investing/2024/12/15/up-152-in-december-is-uniqure-a-good-stock-to-buy/?source=eptyholnk0000202&utm_source=yahoo-host-full&utm_medium=feed&utm_campaign=article&referring_guid=c011d56f-08cf-4fe8-8d42-28c7ccfe097e",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/152-december-uniqure-good-stock-093100633.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    },
    {
        "id": "1757c584-998a-38be-a8c7-55a8d79a00af",
        "content": {
            "id": "1757c584-998a-38be-a8c7-55a8d79a00af",
            "contentType": "STORY",
            "title": "QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug",
            "description": "",
            "summary": "uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.",
            "pubDate": "2024-12-11T15:02:00Z",
            "displayTime": "2024-12-11T15:02:00Z",
            "isHosted": true,
            "bypassModal": false,
            "previewUrl": null,
            "thumbnail": {
                "originalUrl": "https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad",
                "originalWidth": 635,
                "originalHeight": 400,
                "caption": "",
                "resolutions": [
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/woEWcNDZGH_3gLX_.sdY1g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad",
                        "width": 635,
                        "height": 400,
                        "tag": "original"
                    },
                    {
                        "url": "https://s.yimg.com/uu/api/res/1.2/weOPIkQr22MZJSgDImB0Bg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad",
                        "width": 170,
                        "height": 128,
                        "tag": "170x128"
                    }
                ]
            },
            "provider": {
                "displayName": "Zacks",
                "url": "http://www.zacks.com/"
            },
            "canonicalUrl": {
                "url": "https://finance.yahoo.com/news/qure-soars-fda-alignment-speedy-150200885.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "clickThroughUrl": {
                "url": "https://finance.yahoo.com/news/qure-soars-fda-alignment-speedy-150200885.html",
                "site": "finance",
                "region": "US",
                "lang": "en-US"
            },
            "metadata": {
                "editorsPick": false
            },
            "finance": {
                "premiumFinance": {
                    "isPremiumNews": false,
                    "isPremiumFreeNews": false
                }
            },
            "storyline": null
        }
    }
]